GLP-1 Personalized Medicine: Who Responds Best—and How Can You Tell?

Most people taking GLP-1 medications for diabetes or weight management see meaningful results—but not everyone responds the same way. Recent research confirms there’s real variation, and it’s normal to wonder: can anyone predict who will benefit most from these medicines, and what should you do if you’re not seeing the expected changes?

Why Response to GLP-1 Medications Varies

GLP-1 personalized medicine is a growing field focused on tailoring treatment to each person’s unique biology and circumstances. Studies show some people lose far more weight or see greater improvements in blood sugar than others, even when taking the same medication at similar doses. According to a large 2026 narrative review, about 10% of people with obesity in clinical trials for GLP-1 and dual GLP-1/GIP medications lose less than 5% of their body weight—classifying them as "non-responders." In real-world settings, this number may be even higher. For people with type 2 diabetes, most see some improvement in blood sugar, but a small group experiences little to no glycemic benefit (Kuryłowicz, Diabetes Obesity Metabolism, 2026).

So what explains these differences?

Key Predictors from Real-World Evidence

Across multiple large studies, some of the most consistent predictors of strong response to GLP-1 medications include:

• Early on-treatment response: How much weight or HbA1c you lose in the first 1–3 months is the best signal of your longer-term results. In a major real-world cohort, over half of the total weight loss at 6 months happened in the first 3 months (Nature Medicine, 2026).
• Sex: Women are about twice as likely as men to be "super-responders" (losing >15% of their starting weight) in several studies (PMC, 2026, PMC, 2026).
• Baseline characteristics: Higher starting HbA1c predicts greater HbA1c reduction in type 2 diabetes, and higher baseline weight sometimes predicts more absolute weight loss in women (PubMed, 2022).
• Behavioral factors: People who set specific goals or had a history of structured diet attempts tended to have better weight loss on tirzepatide, a dual GLP-1/GIP agonist (Endocrine Society, 2026).
• Demographics: Younger age, not having diabetes or hypertension, and certain comorbidities may be linked to better outcomes, but these findings are still being explored (PMC, 2026).

What About Genetics and Biomarkers?

There’s a lot of excitement about the possibility of using genetic or biological tests to predict medication response. Some genetic variants—such as those in the GLP1R, ARRB1, and PAM genes—have been linked to smaller changes in blood sugar or weight on GLP-1 medications, but the effect sizes are modest. For example, people with certain loss-of-function GLP1R variants may see about 0.9–6.2 mmol/mol less HbA1c reduction per allele. Right now, genetic testing is not practical or recommended for routine care, and these findings aren’t used to guide clinical decisions yet (Diabetes Care, 2026).

Other potential predictors—like microbiome profiles, hormone levels, or metabolic markers—are still considered experimental. More research is needed before they can help guide therapy for most people (Frontiers in Medicine, 2026).

The Most Actionable Predictor: Early Response

Given the current evidence, the best way to personalize GLP-1 treatment is by tracking your progress closely in the first few months:

• For weight management: If you haven’t lost at least 5% of your starting weight by 16–24 weeks at the maximum tolerated dose, you’re often considered a "non-responder." Moderate response is 5–10%, good is 10–20%, and super-response is ≥20% (MDPI, 2026).
• For diabetes: A reduction in HbA1c of at least 0.5–1.0% is considered a meaningful response. Higher starting HbA1c often means more room for improvement (PubMed, 2022).

Early weight or blood sugar changes are not just numbers—they help you and your clinician decide whether to keep going, adjust the dose, reinforce behavioral supports, or consider switching to a different medication or approach. Tracking your symptoms and results in an app like GLPily can make these conversations more productive and less stressful.

Why Some People Respond Less—and What to Do Next

Not seeing the results you hoped for can be frustrating, but you’re not alone. Real-world studies show a significant portion of people on GLP-1 medications lose less than 5% of their weight, or even regain weight after an initial drop (PMC, 2026). Factors like sex, age, baseline health, and even prior behavioral habits can all play a role, but sometimes the reason is simply unknown.

If you’re not responding as expected, practical next steps may include:

• Reviewing your medication dose and schedule (never change this without your clinician’s guidance)
• Reinforcing or adding behavioral support, such as dietary counseling or structured goal-setting
• Evaluating for side effects that might be limiting your progress
• Considering a switch to a different GLP-1 medication or another weight management approach if, after 16–24 weeks, response is minimal (MDPI, 2026)

For more on what counts as a response and what to do if you’re not losing weight, see What Counts as Response on Weight Loss Medication? and Doctor Review: What If GLP-1 Isn’t Helping?.

Questions to Ask Your Doctor About GLP-1 Personalized Medicine

Here are some practical questions you can bring to your next appointment:

1. How soon will we know if this medication is working for me?
2. What changes in weight or blood sugar should I expect by the 3- or 4-month mark?
3. If my results are less than expected, what are our options—dose adjustment, behavioral support, switching medications?
4. Do any of my personal factors (like age, sex, diabetes status, or other health conditions) affect my likely response?
5. Are there structured check-ins or tools (like tracking apps) we can use to monitor my progress?

What We Still Don’t Know

While early response and some demographic factors are helpful guides, many other predictors—especially genetic markers—are promising but not ready for routine clinical use. Research is ongoing, and new tools may emerge in the coming years. For now, the focus remains on structured early monitoring, open communication, and individualized care.

If you’re curious about switching medications, see Practical Challenges of Switching and Cross-Titration Between Incretin-Based Therapies and Why Some People Respond Less to GLP-1.

Bottom Line

GLP-1 personalized medicine is advancing, but there’s no crystal ball—yet. The best way to predict your response is to track your progress early, discuss milestones with your clinician, and work together on next steps if things aren’t moving as hoped. Everyone’s journey is different, and your care can be tailored to your needs as you go.